3 news items
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
LUMO
14 May 24
change for patients. Please keep in mind that actual results or events could differ materially from the plans, intentions and expectations disclosed
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
LUMO
20 Mar 24
. Please keep in mind that actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
LUMO
7 Mar 24
results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make
- Prev
- 1
- Next